Difference between revisions of "Infigratinib (Truseltiq)"
Jump to navigation
Jump to search
m |
m (Jwarner moved page Infigratinib (BGJ398) to Infigratinib (Truseltiq): FDA approval with new brand name) |
(No difference)
| |
Revision as of 01:44, 2 June 2021
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death.
Diseases for which it is used
History of changes in FDA indication
- 5/28/2021: Accelerated approval for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Based on CBGJ398X2204)
Also known as
- Code name: BGJ398
- Brand name: Truseltiq